MORF - Morphic Holding Inc Stock Price, Fair Value and News

$56.990.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MORF Price Action

Last 7 days

0.2%

Last 30 days

1.3%

Last 90 days

95.0%

Trailing 12 Months

12.3%

MORF RSI Chart

MORF Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-15.92

Price/Sales (Trailing)

5.4K

EV/EBITDA

-15.78

Price/Free Cashflow

-20.79

MORF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MORF Fundamentals

MORF Revenue

MORF Earnings

Earnings (TTM)

-179.8M

Earnings Growth (Yr)

-47.6%

Earnings Growth (Qtr)

-27.14%

MORF Profitability

EBT Margin

-34413.82%

Return on Equity

-29.08%

Return on Assets

-27.83%

Free Cashflow Yield

-4.81%

MORF Investor Care

Shares Dilution (1Y)

4.80%

Diluted EPS (TTM)

-3.78

MORF Alerts

Point72 Asset Management, L.P. reported owning 0% of MORF [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	53.2M	35.7M	18.1M	521.0K
2022	32.5M	45.3M	58.1M	70.8M
2021	42.6M	38.8M	16.1M	19.8M
2020	24.0M	31.0M	38.0M	44.9M
2019	9.1M	14.9M	20.7M	17.0M
2018	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ÃƒÆ’Ã…Â¸7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ÃƒÆ’Ã…Â¸7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avÃƒÆ’Ã…Â¸8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with SchrÃƒÆ’Ã‚Â¶dinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Praveen P. Tipirneni M.D.
WEBSITE	morphictx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	110

Morphic Holding Inc Frequently Asked Questions

What is the ticker symbol for Morphic Holding Inc? What does MORF stand for in stocks?

MORF is the stock ticker symbol of Morphic Holding Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Morphic Holding Inc (MORF)?

As of Fri Aug 16 2024, market cap of Morphic Holding Inc is 2.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MORF stock?

You can check MORF's fair value in chart for subscribers.

Is Morphic Holding Inc a good stock to buy?

The fair value guage provides a quick view whether MORF is over valued or under valued. Whether Morphic Holding Inc is cheap or expensive depends on the assumptions which impact Morphic Holding Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MORF.

What is Morphic Holding Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Aug 16 2024, MORF's PE ratio (Price to Earnings) is -15.92 and Price to Sales (PS) ratio is 5.44 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MORF PE ratio will change depending on the future growth rate expectations of investors.